NGM Biopharmaceuticals, Inc. (NGM)
| Market Cap | 1.63B |
| Revenue (ttm) | 84.58M |
| Net Income (ttm) | -110.92M |
| Shares Out | 76.03M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $21.22 |
| Previous Close | $21.20 |
| Change ($) | 0.02 |
| Change (%) | 0.09% |
| Day's Open | 21.36 |
| Day's Range | 20.51 - 22.21 |
| Day's Volume | 127,880 |
| 52-Week Range | 14.90 - 32.12 |
NGM Biopharmaceuticals (NGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NGM Biopharmaceuticals Inc (NASDAQ: NGM) has amended and restated an agreement with Merck & Co Inc (NYSE: MRK) to extend their ongoing collaboration through March 2024 with a narrower scope. The collab...
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known as...
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...
Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Bio...
Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Bio...
Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Bio...
LOS ANGELES, May 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceuticals, ...
LOS ANGELES--(BUSINESS WIRE)---- $NGM #NGM--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc.
The results of a hepatitis drug candidate's clinical trial were not good.
LOS ANGELES--(BUSINESS WIRE)---- $NGM #NGM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc.
Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The primary endpoint of an improvement in fibrosis wi...
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.
NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fi...
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics ...
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. P...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.29% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutic...
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.89% and -14.45%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutic...
--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase 2 study of NGM621 in patients with geographi...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
– Event to showcase NGM's multi-therapeutic area p ipeline , including its oncology por tfolio and Geographic Atrophy and NASH programs –
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular infl...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-a...
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate NGM Biopharmaceuticals (NGM) to Report a Decline in Earnings: What to Look Out for
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...
-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a progressive,...
NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, ...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enrollment in...
SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVI...
Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.
NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16.
SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, toda...
Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.
About NGM
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for u... [Read more...]
| Industry Biotechnology | IPO Date Apr 4, 2019 |
| CEO David Woodhouse | Employees 210 |
| Stock Exchange NASDAQ | Ticker Symbol NGM |
Analyst Forecasts
According to 9 analysts, the average rating for NGM stock is "Strong Buy." The 12-month stock price forecast is 24.50, which is an increase of 15.46% from the latest price.